A study using an FLT3-transfected cell model to create an FLT3-mutated or FLT3 wild-type phenotype in T-ALL cell lines showed sensitivity towards sorafenib in FLT3-mutated cell lines, although the cell lines used in that study did not exhibit the ETP-ALL phenotype (108). This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.